BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250906T033318EDT-3932iPrUAD@132.216.98.100
DTSTAMP:20250906T073318Z
DESCRIPTION:Abstract:\n\nInterdisciplinary tools in drug development have e
 xtended the limitations of modern therapeutics. We are now able to address
  a vast array of diseases with previously unmet needs\, however\, there pe
 rsists limitations in the understanding of molecular drivers of diseases\,
  and biology which remains elusive or undruggable. These limitations are h
 ighlighted within inflammatory diseases where treatment still focuses on a
 lleviating symptoms. This paradigm leaves 65% of patients non-responsive t
 o current drugs\, resulting in up to $85 billion in wasted drug spend ever
 y year.\n\nSeeking to address these unmet needs\, our focus is on an attra
 ctive class of biologically potent yet largely undruggable targets\; trans
 cription factors (TFs). Master regulators of biology\, TFs translate intra
 cellular signals into selective\, cell-specific genetic expression\; profo
 undly altering cell development\, homeostasis\, and metabolism. Historical
 ly challenging targets\, particularly for small molecule drug development\
 , recent advances have shed light on strategies for biased amino acid enga
 gement within the target ligand binding pocket target and orthogonal pathw
 ay augmentation.\n\nSupported by a systems biology and computer assisted a
 pproach\, we are working to pioneer the development of novel small molecul
 e therapeutics which leverage biased engagement of TFs to simultaneously r
 esolve dysregulated immune and barrier transcriptional pathways. Through t
 his approach\, we seek to transform the treatment of complex unmet needs w
 ithin inflammatory diseases involving barrier dysfunction.\n\n \n\nBio:\n
 \nCarla Spina\, Ph.D. is a scientific innovator and entrepreneur dedicated
  to improving the lives of patients living with complicated diseases. Carl
 a graduated with a B.Sc. from the University of Calgary then began her Ph.
 D. in 2003 in Bioinorganic Chemistry at ºÚÁÏÉç under Dr. D.S. B
 ohle\, the Canadian Chair in Bioinorganic chemistry. Under the guidance of
  Dr. Bohle\, Carla set about integrating the principles of chemistry\, bio
 logy\, and infectious disease to increase understanding of human disease. 
 Building upon her expertise at the intersection of chemistry and biology s
 he trained in applied formulations at BASF in Germany then went on to lead
  the research team at a MedTech start-up developing Class II/III drug-devi
 ces for infectious disease prevention. During this time\, she guided resea
 rch from concept through to commercialization\, resulting in global licens
 es through 3M. Following this role\, she co-founded a biotech start-up foc
 used on novel therapeutics for complicated skin and skin structure infecti
 on. Within this role\, Carla drove the company from drug discovery through
  to Phase Ib/IIa clinical study\, establishing a network of KOLs\, consult
 ants\, advisors\, and research foundations to tackle diseases considered a
  complication of diabetes. Leveraging her experience from drug discovery t
 hrough to clinical phase studies\, Carla is now leading the team at Noa Th
 erapeutics\, a preclinical Canadian biotech company aiming to defy the con
 vention of traditional drug development to revolutionize treatment options
  for those living with complex inflammatory skin diseases. \n\n \n
DTSTART:20241119T180000Z
DTEND:20241119T193000Z
LOCATION:OM 10\, Maass Chemistry Building\, CA\, QC\, Montreal\, H3A 0B8\, 
 801 rue Sherbrooke Ouest
SUMMARY:Chemical Society Seminar (Brown Lecture): Carla Spina- Exploring li
 gand dependent signal transduction to transform the treatment of inflammat
 ory barrier disease
URL:/chemistry/channels/event/chemical-society-seminar
 -brown-lecture-carla-spina-exploring-ligand-dependent-signal-transduction-
 358413
END:VEVENT
END:VCALENDAR